You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAfelimomab
Accession NumberDB04956
TypeBiotech
GroupsInvestigational
DescriptionAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
Protein structureDb04956
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
Synonyms
Fab 2
MAK 195F
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SegardNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6SC756X51V
CAS number156227-98-4
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationInvestigated for use/treatment in sepsis and septicemia.
PharmacodynamicsAfelimomab is the F(ab')2 fragment of a murine anti-TNF-alpha antibody, and has been evaluated in clinical trials in septic patients. The results suggest that the drug is well tolerated, and may be of benefit in certain groups of patients with sepsis. Afelimomab is safe, biologically active, and well tolerated in patients with severe sepsis, reduces 28-day all-cause mortality, and attenuates the severity of organ dysfunction in patients with elevated interleukin-6 levels.
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life44.7 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
References
Synthesis ReferenceNot Available
General References
  1. Vincent JL: Afelimomab. Int J Clin Pract. 2000 Apr;54(3):190-3. [PubMed:10829362 ]
  2. Gallagher J, Fisher C, Sherman B, Munger M, Meyers B, Ellison T, Fischkoff S, Barchuk WT, Teoh L, Velagapudi R: A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med. 2001 Jul;27(7):1169-78. [PubMed:11534565 ]
External Links
ATC CodesL04AB03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbataceptThe risk or severity of adverse effects can be increased when Afelimomab is combined with Abatacept.
AnakinraThe risk or severity of adverse effects can be increased when Afelimomab is combined with Anakinra.
CanakinumabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Canakinumab.
Certolizumab pegolAfelimomab may increase the immunosuppressive activities of Certolizumab pegol.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Afelimomab.
FingolimodAfelimomab may increase the immunosuppressive activities of Fingolimod.
LeflunomideThe risk or severity of adverse effects can be increased when Afelimomab is combined with Leflunomide.
NatalizumabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Natalizumab.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Afelimomab.
Rabies vaccineThe risk or severity of adverse effects can be increased when Afelimomab is combined with Rabies vaccine.
RilonaceptThe risk or severity of adverse effects can be increased when Afelimomab is combined with Rilonacept.
RoflumilastRoflumilast may increase the immunosuppressive activities of Afelimomab.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Afelimomab.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Afelimomab.
TocilizumabTocilizumab may increase the immunosuppressive activities of Afelimomab.
TofacitinibThe risk or severity of adverse effects can be increased when Afelimomab is combined with Tofacitinib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Afelimomab.
VedolizumabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Vedolizumab.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Vincent JL: Afelimomab. Int J Clin Pract. 2000 Apr;54(3):190-3. [PubMed:10829362 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24